Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC

Journal of the American Academy of Dermatology

Volumn 72, Issue 6, 2015, Pages 1021-1026.e8

  Sekulic, Aleksandar ^a   Migden, Michael R ^b   Lewis, Karl ^c   Hainsworth, John D ^d   Solomon, James A ^e,f,g   Yoo, Simon ^h   Arron, Sarah T ⁱ   Friedlander, Philip A ^j,k   Marmur, Ellen ^k   Rudin, Charles M ^l   Chang, Anne Lynn S ^m   Dirix, Luc ⁿ   Hou, Jeannie ^o   Yue, Huibin ^o   Hauschild, Axel ^p  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^d SARAH CANNON RESEARCH INSTITUTE   (United States)

^e Ameriderm Research   (United States)

^f UNIVERSITY OF CENTRAL FLORIDA   (United States)

^g UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j DANA FARBER CANCER INSTITUTE   (United States)

^k MOUNT SINAI MEDICAL CENTER   (United States)

^l JOHNS HOPKINS UNIVERSITY   (United States)

^m STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ SINT AUGUSTINUS HOSPITAL   (Belgium)

^o GENENTECH INC   (United States)

^p UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

more..

Author keywords

advanced basal cell carcinoma; ERIVANCE BCC study; Hedgehog pathway inhibitor; locally advanced basal cell carcinoma; metastatic basal cell carcinoma; vismodegib

Indexed keywords

SONIC HEDGEHOG PROTEIN; VISMODEGIB; ANILIDE; PYRIDINE DERIVATIVE;

ADVANCED CANCER; ALOPECIA; AMENORRHEA; ARTICLE; BASAL CELL CARCINOMA; BODY WEIGHT DISORDER; CANCER GROWTH; CANCER STAGING; COHORT ANALYSIS; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; FATIGUE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; ADULT; AGED; CARCINOMA, BASAL CELL; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; RISK ASSESSMENT; SKIN NEOPLASMS; STATISTICS AND NUMERICAL DATA; SURVIVAL; TIME; TREATMENT OUTCOME; TUMOR INVASION; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANILIDES; CARCINOMA, BASAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SAFETY; PYRIDINES; RISK ASSESSMENT; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929629820     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2015.03.021     Document Type: Article

References (12)

1. D. Göppner, and M. Leverkus Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease J Skin Cancer 2011 2011 650258
2. F. Cirrone, and C.S. Harris Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma Clin Ther 34 2012 2039 2050
3. J. Reifenberger, M. Wolter, and R.G. Weber Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system Cancer Res 58 1998 1798 1803
4. J. Xie, M. Murone, and S.-M. Luoh Activating smoothened mutations in sporadic basal-cell carcinoma Nature 391 1998 90 92
5. I. Caro, and J.A. Low The role of the hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment Clin Cancer Res 16 2010 3335 3339
6. L. Daya-Grosjean, and S. Couvé-Privat Sonic hedgehog signaling in basal cell carcinomas Cancer Lett 225 2005 181 192
7. A. Sekulic, M.R. Migden, and A.E. Oro Efficacy and safety of vismodegib in advanced basal-cell carcinoma N Engl J Med 366 2012 2171 2179
8. FDA approves new treatment for most common type of skin cancer [press release] January 30, 2012 US Food and Drug Administration Silver Spring (MD) Available from: URL http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm289545.htm Accessed April 2, 2014
9. Erivedge [prescribing information] 2012 Genentech South San Francisco, CA
10. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events v3.0 (CTCAE) 2006 National Cancer Institute, US National Institutes of Health Bethesda (MD) Available from: URL http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf Accessed April 2, 2014
11. T.L. Lin, and W. Matsui Hedgehog pathway as a drug target: smoothened inhibitors in development Onco Targets Ther 5 2012 47 58
12. J.T. Lear Oral hedgehog-pathway inhibitors for basal-cell carcinoma N Engl J Med 366 2012 2225 2226